Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Leuk Lymphoma. 2013 Feb;54(2):290-7. doi: 10.3109/10428194.2012.711830. Epub 2012 Sep 6.

The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma.

Author information

  • 1Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA. yost.kathleen@mayo.edu

Abstract

Quality of life (QoL) is an important outcome in patients with non-Hodgkin lymphoma (NHL). We assessed the validity of administering the Functional Assessment of Cancer Therapy - General (FACT-G) at 12-month intervals over 3 years in a longitudinal study of 611 prospectively enrolled, newly diagnosed patients with NHL. We evaluated corrected item-total correlation and percent missing to identify items that may be less useful in certain NHL patient subgroups. The FACT-G subscales and total score demonstrated good internal consistency reliability, convergent validity and known-groups validity. Most scores also demonstrated good responsiveness to change. Questions that could be problematic included GE3 (losing hope) and GP2 (nausea) for patients in remission, and GP5 (bothered by side effects) for patients being observed. Overall, the FACT-G was a valid measure for monitoring QoL over time in patients with NHL. However, sensitivity analyses based on subscale scoring that excludes potentially problematic items may be warranted.

PMID:
22799432
[PubMed - indexed for MEDLINE]
PMCID:
PMC3665161
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk